Vazyme Signs Global Strategic Cooperation Agreement with Azenta
NANJING, China, May 31, 2023 /PRNewswire/ -- Vazyme (688105.SH), China's leading biotechnology company, has officially signed a global strategic cooperation agreement with Azenta Life Sciences ("Azenta", Nasdaq: AZTA), which will promote to establish "one-stop" service process for both companies ...
Ready to Enter the Middle East Market, Vazyme Showcases Its COVID-19 Testing Solutions at Medlab Middle East 2022
DUBAI, UAE, Jan. 28, 2022 /PRNewswire/ -- Leading China-based biotech company Vazyme (688105.SH) participated in the 2022 edition of Medlab Middle East in the Dubai World Trade Centre (DWTC) fromJanuary 24th to 27th, a leading laboratory and flagship exhibition and conference that brings together...
Vazyme Attends Medica 2021 in Germany to Accelerate Its Global Market Expansion
DUSSELDORF, Germany, Nov. 19, 2021 /PRNewswire/ -- Chinese biotechnology company Vazyme (688105.SH) recently attended Medica 2021 in Germany—one of the world's largest events for the medical sector—to accelerate the expansion of its international business. At the event, Vazyme introduced its newe...
Vazyme goes public on Shanghai Stock Exchange today
NANJING, China, Nov. 15, 2021 /PRNewswire/ -- On November 15, 2021, Nanjing
Vazyme Biotech Co., Ltd. (Vazyme) went public on the STAR MARKET of the
Shanghai Stock Exchange under the stock code 688105.
